NASDAQ •
Healthcare •
Biotechnology •
Quote as of 09/08/2026 11:17
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,824.67 mln
Float321 mln
Earnings Date11/10/2026
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
-3.36
Reliable
1-Year Forecast
13.33
Transformational upside
Relative Strength
14
/ 100
Significantly lagging
Debt / Equity
0.15
Very low leverage
Pre-Tax Margin
-2,728%
Severely loss-making
Business Description
Taysha Gene Therapies is a Dallas-based biotech company working to develop gene therapies for rare and serious brain and nervous system disorders caused by single gene defects. Founded in 2019, the company has a pipeline of treatments targeting conditions such as Rett syndrome, giant axonal neuropathy, and fragile X syndrome, among others. Taysha works in partnership with the University of Texas Southwestern Medical Center to advance its research.
